{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.","groups":[{"description":"Alisertib was administered PO at 50 mg BID for 7 days in each treatment cycle, followed by a 14-day, treatment-free period, for a 21-day cycle.","id":"OG000","title":"Alisertib"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"1 patient did not complete one cycle of treatment and 25 patients were evaluable for efficacy.","reportingStatus":"POSTED","timeFrame":"From treatment start, every 6 weeks until progression, death, withdrawal of consent or study completion an average of 25 months","title":"Overall Response Rate","type":"SECONDARY","unitOfMeasure":"Participants"}